IN VIVO

Scope & Guideline

Driving impactful discoveries in the fight against cancer.

Introduction

Delve into the academic richness of IN VIVO with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0258-851x
PublisherINT INST ANTICANCER RESEARCH
Support Open AccessNo
CountryGreece
TypeJournal
Convergefrom 1987 to 2024
AbbreviationIN VIVO / In Vivo
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE

Aims and Scopes

The journal "IN VIVO" primarily focuses on the translational aspects of biological and medical research, emphasizing in vivo studies that bridge laboratory findings and clinical applications. This journal serves as a platform for sharing innovative research that contributes to understanding disease mechanisms, treatment strategies, and therapeutic interventions.
  1. Translational Medicine:
    Research that connects laboratory findings with clinical applications, aiming to enhance patient care and treatment outcomes.
  2. Oncology and Cancer Research:
    A significant focus on various aspects of cancer research, including novel treatment modalities, prognostic factors, and molecular mechanisms underlying tumorigenesis.
  3. Pharmacology and Drug Development:
    Studies exploring drug efficacy, mechanisms of action, and the impact of pharmacogenomics on treatment responses.
  4. Regenerative Medicine and Tissue Engineering:
    Research involving stem cells, tissue scaffolds, and regenerative therapies to repair or replace damaged tissues.
  5. Immunology and Inflammatory Diseases:
    Investigations into immune responses, inflammation processes, and their implications in various diseases, particularly cancer and autoimmune conditions.
  6. Surgical Techniques and Outcomes:
    Evaluation of surgical interventions, including innovative surgical techniques, their effectiveness, and patient outcomes.
  7. Biomarkers and Diagnostic Tools:
    Research aimed at identifying novel biomarkers for disease diagnosis, prognosis, and monitoring therapeutic responses.
As the journal "IN VIVO" evolves, certain themes are emerging as key areas of focus. This section outlines these trending scopes, indicating the directions in which research is increasingly heading.
  1. Precision Medicine and Personalized Therapies:
    Research focused on tailoring treatments to individual patient characteristics, including genetic profiling and targeted therapies, is gaining momentum.
  2. Immunotherapy and Cancer Vaccines:
    An increase in studies exploring the efficacy and mechanisms of immunotherapy and novel cancer vaccines, reflecting the growing importance of these approaches in oncology.
  3. Regenerative Medicine Innovations:
    Emerging techniques in regenerative medicine, including the application of stem cells and biomaterials for tissue repair, are becoming more prevalent.
  4. Artificial Intelligence in Medical Research:
    The integration of artificial intelligence and machine learning in analyzing research data, predicting outcomes, and improving diagnostic accuracy is on the rise.
  5. Longitudinal Studies on Treatment Outcomes:
    A trend towards conducting long-term studies that assess the outcomes of various treatment modalities in cancer and other chronic diseases.
  6. Microbiome Research:
    Increasing interest in the role of the microbiome in health, disease progression, and treatment efficacy, particularly in cancer therapy.

Declining or Waning

While "IN VIVO" continues to thrive in various research areas, certain themes appear to be declining in prominence. This section identifies these waning scopes, highlighting the potential shift in research focus within the journal.
  1. Basic Science Research:
    There seems to be a decline in purely basic science studies that do not translate into clinical applications, as the journal increasingly prioritizes research with direct clinical relevance.
  2. Animal Models of Non-Oncological Diseases:
    Research focusing on animal models for diseases other than cancer appears less frequent, possibly due to a greater emphasis on cancer-related studies and translational impacts.
  3. Epidemiological Studies:
    Epidemiological research that does not directly tie into clinical interventions or outcomes has seen reduced representation, suggesting a shift towards more intervention-focused studies.
  4. Traditional Diagnostic Methods:
    There is a noticeable decrease in studies focusing on conventional diagnostic methods, as the journal shifts towards innovative techniques and biomarkers.

Similar Journals

Translational Research

Transforming Science into Health Solutions
Publisher: ELSEVIER SCIENCE INCISSN: 1931-5244Frequency: 12 issues/year

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

Asian Biomedicine

Connecting Researchers to Transform Healthcare
Publisher: WALTER DE GRUYTER GMBHISSN: 1905-7415Frequency: 6 issues/year

Asian Biomedicine, published by WALTER DE GRUYTER GMBH, serves as a crucial platform for disseminating pioneering research in the field of biomedical sciences. Established in 2008, this journal has carved its niche in the landscape of academic publishing, concentrating on a diverse array of topics within biochemistry, genetics, and molecular biology, as well as medicine. Though it currently holds a Q4 ranking in its category, it is dedicated to fostering academic discussions and advancing knowledge among researchers, professionals, and students alike. While the journal features a variety of access options, it is committed to ensuring that its content remains relevant and impactful, with an emphasis on the latest developments and research trends. The editorial board encourages submissions that address pressing biomedical issues, thus empowering contributors to engage meaningfully with the scientific community. With a broad international scope and a focus on quality, Asian Biomedicine is poised to play an increasingly important role in the advancement of biomedical research in Asia and beyond.

Biomedicines

Innovating research at the intersection of medicine and molecular biology.
Publisher: MDPIISSN: Frequency: 12 issues/year

Biomedicines, published by MDPI, is a prestigious open-access journal dedicated to the rapidly evolving fields of biochemistry, genetics, and molecular biology, as well as broader aspects of medicine. Since its inception in 2013, Biomedicines has established itself as a leading platform for researchers, practitioners, and students to disseminate high-quality research and innovative findings, reflected in its impressive Q1 ranking in both the Biochemistry, Genetics and Molecular Biology and Medicine categories. With its commitment to accessibility and impactful scholarship, the journal has quickly garnered an international readership, positioning itself as a vital resource in advancing scientific knowledge and fostering collaboration in the biomedical community. Operating from its headquarters in Basel, Switzerland, Biomedicines continues to thrive with features such as rigorous peer review and a fast publication process, making it an essential journal for those looking to contribute to and stay updated in their respective fields.

BIOCELL

Fostering Excellence in Cell Research
Publisher: TECH SCIENCE PRESSISSN: 0327-9545Frequency: 12 issues/year

BIOCELL is a distinguished peer-reviewed journal dedicated to the field of Cell Biology, published by TECH SCIENCE PRESS. Since its inception in 1995, the journal has been at the forefront of disseminating innovative research, with converged publication years extending from 1995 to 2013 and from 2015 to 2024. Although it currently holds a Q4 ranking in the Cell Biology category according to the 2023 category quartiles, BIOCELL aims to foster advancements by providing a platform for researchers, professionals, and students to share their findings in biochemistry, genetics, and molecular biology. The journal is available in both print (ISSN: 0327-9545) and digital formats (E-ISSN: 1667-5746) and seeks to attract contributions that enhance scholarly dialogue and understandings of cellular mechanisms and innovations. With a commitment to quality research and critical discourse, BIOCELL plays an important role in nurturing the scientific community within Argentina and beyond, offering vital insights that contribute to the advancement of the life sciences.

Molecular and Clinical Oncology

Connecting researchers to revolutionize cancer treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

EXPERIMENTAL AND MOLECULAR PATHOLOGY

Advancing the frontiers of disease understanding.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0014-4800Frequency: 6 issues/year

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Transforming Cancer Knowledge into Impactful Solutions
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

LIFE SCIENCES

Driving excellence in peer-reviewed life sciences research.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0024-3205Frequency: 24 issues/year

LIFE SCIENCES, published by PERGAMON-ELSEVIER SCIENCE LTD, is an esteemed international journal that has been advancing the field since its inception in 1962. With an ISSN of 0024-3205 and an E-ISSN of 1879-0631, it serves as a critical forum for researchers, professionals, and students within the realms of biochemistry, genetics, molecular biology, medicine, and pharmacology. Currently ranked in the Q1 category across multiple disciplines, including a remarkable 2nd rank in General Pharmacology, Toxicology, and Pharmaceutics, the journal maintains a prestigious position in academic circles, evidenced by its high impact factor and significant percentile ranks. While LIFE SCIENCES is not an open-access journal, it remains dedicated to publishing high-quality, peer-reviewed research that pushes the boundaries of knowledge and fosters innovation. With converged research interests leading into 2024, LIFE SCIENCES continues to be a pivotal resource for the dissemination of influential findings, making it an indispensable tool for those engaged in the life sciences.

International Journal of Molecular and Cellular Medicine

Empowering Research in Molecular Medicine and Beyond
Publisher: CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTERISSN: 2251-9637Frequency: 4 issues/year

International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.

Molecular Biomedicine

Pioneering Discoveries in Molecular Biology and Medicine
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.